Physician profile
Brett Inglis
NPI 1972718104
$14,276.80
in general payments reported to CMS, 2019-2025
41 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $1,111 · 2021: $1,752 · 2022: $2,015 · 2023: $2,082 · 2024: $2,642 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,580.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,764.98 | 2019-2025 | |
| Gilead Sciences, INC. | $1,980.98 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,724.02 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $915.25 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $723.87 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $719.85 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $504.11 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $363.60 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $284.57 | 2024-2025 | Zenpep |
| Genzyme Corporation | $226.17 | 2022-2025 | |
| Madrigal Pharmaceuticals | $220.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $218.14 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $196.66 | 2019-2022 | |
| Endogastric Solutions, INC | $131.01 | 2023 | Esophyx |
| Celltrion USA INC. | $104.99 | 2025 | Vegzelma |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Inglis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.